Core Viewpoint - Genomma Lab Internacional reported a modest sales growth of 0.5% in Q2 2025, with a notable increase in profitability metrics despite macroeconomic challenges, particularly in Argentina and Mexico [2][5][6]. Financial Performance - Net sales reached 4,676.4 million pesos, reflecting a 0.5% increase compared to Q2 2024, or a 5.5% increase when excluding Argentina [5]. - Like-for-like sales showed a growth of 0.3% [5]. - Gross profit was 2,969.4 million pesos, representing 63.5% of net sales, a slight decrease of 0.3% from the previous year [5]. - Operating income increased by 4.8% to 1,030.6 million pesos, accounting for 22.0% of net sales [5]. - EBITDA grew by 4.4% to 1,112.9 million pesos, with a margin of 23.8%, an increase of 89 basis points [5][6]. - Net income decreased by 43.8% to 355.0 million pesos, primarily due to significant non-cash foreign exchange losses [5][6]. - Proforma net income, excluding non-cash FX effects, increased by 16.6% to 667.8 million pesos [7]. Profitability Metrics - The EBITDA margin expanded to 23.8%, driven by manufacturing cost efficiencies and a favorable sales mix [6]. - Proforma EPS increased by 16.6% to 0.67 pesos per share, reflecting improved operating income and lower net interest expenses [7]. Cash Flow and Operational Efficiency - Free cash flow increased by 64.6% over the trailing twelve months, supported by a 7-day improvement in the cash conversion cycle [2]. Market Context - The company faced challenges from an 18.3% depreciation of the Argentine peso and a weak beverage season in Mexico, but experienced robust growth in the US, Brazil, Central America, and the Andean region [5]. Company Overview - Genomma Lab is a leading pharmaceutical and personal care products company in Mexico, with a growing international presence and a focus on premium branded products [10].